The board of the biotechnology company BioNexus Gene Lab approved the allocation of part of its funds to the Ethereum ecosystem

ChainCatcher news, according to Globe Newswire, the board of directors of the biotech company BioNexus Gene Lab Corp has approved a treasury strategy for Ethereum and released a related strategic white paper, allocating part of its funds to the Ethereum ecosystem.

The company stated that this strategy aims to optimize financial management while exploring the potential applications of blockchain technology in the biotech field. The strategic white paper elaborates on how the company plans to leverage the smart contract capabilities and decentralized features of the Ethereum network to create new opportunities for its business development.